On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma by Gholamrezanezhad, Ali et al.
100
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 58; Numer/Number 2/2007
ISSN 0423104X
On-levothyroxine measurement of thyroglobulin is not
a reliable test for the follow-up of patients at high risk for
remnant/recurrent differentiated thyroid carcinoma
Monitorowanie stŒ¿enia tyreoglobuliny w trakcie terapii lewotyroksyn„
u chorych na zró¿nicowanego raka tarczycy nie jest wiarygodn„ metod„
wykrywania nawrotu choroby
Ali Gholamrezanezhad, Mohsen Saghari, Sahar Mirpour, Davood Beiki, Ali Tarbiat, Shabnam Javan,
Javaher Abdollahzadeh
Research Institute for Nuclear Medicine, Shariati Hospital, Medical Sciences/University of Teheran, Teheran, Iran
Ali Gholamrezanezhad
Research Institute for Nuclear Medicine,
Shariati Hospital, Medical Sciences/University of Teheran
Northern Kargar St. 14114 Tehran, Iran.




Introduction: At present the most widely accepted tool for follow-up management of differentiated thyroid cancer (DTC)
patients is serum thyroglobulin (Tg) measurement. It is not uncommon for the serum Tg level to be measured while the
patient is taking thyroid hormones (on-treatment Tg measurement). The purpose of the study was to evaluate the accuracy
of on-treatment measurement of serum Tg in detecting remnant/recurrent or metastatic disease in high-risk DTC patients.
Material and methods: We retrospectively analysed the medical records of 26 high-risk DTC patients and compared the
on-treatment and off-treatment Tg levels of these patients. All patients were anti-Tg negative. Using off-treatment measure-
ment of Tg as the gold standard, the results of on-treatment measurement of Tg in the diagnosis of remnant/recurrent
disease were analysed for sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV).
Results: The median serum Tg level under thyroid hormone suppressive therapy (on-treatment Tg) was 16.5 ng/ml and
after withdrawal of thyroid hormone suppressive therapy (off-treatment Tg) was 95.0 ng/ml (P value = 0.001). In 6 patients
(23%) the on-treatment Tg level missed the recurrence of the disease. Regarding the off-treatment Tg as the gold standard,
the sensitivity, specificity, PPV and NPV of the on-treatment Tg measurement were 72.7%, 100%, 100%, and 40% respec-
tively.
Conclusion: Normal serum Tg level without TSH-stimulation (on-treatment) is not diagnostically reliable in the follow-up
of DTC patients with a high probability of residual/recurrent or metastatic disease.
(Pol J Endocrinol 2007; 58 (2): 100104)
Key words: thyroid cancer, serum thyroglobulin, levothyroxine, recurrence
Streszczenie
WstŒp: Obecnie najszerzej akceptowanym narzŒdziem u¿ywanym w badaniach kontrolnych u chorych ze zró¿nico-
wanym rakiem tarczycy jest pomiar osoczowego stŒ¿enia tyreoglobuliny (Tg). Nierzadko zdarza siŒ, i¿ pomiary stŒ¿e-
nia Tg odbywaj„ siŒ, gdy chory jednoczenie przyjmuje preparaty hormonów tarczycowych. Celem niniejszego bada-
nia by‡a ocena przydatnoci pomiaru osoczowego stŒ¿enia Tg w trakcie stosowania hormonów tarczycy w wykrywa-
niu choroby resztkowej/nawrotowej lub obecnoci przerzutów u chorych z wysokim ryzykiem wznowy zró¿nicowa-
nego raka tarczycy.
Materia‡y i metody: Retrospektywnej analizie poddano dokumentacjŒ medyczn„ 26 pacjentów obci„¿onych du¿ym ryzy-
kiem wyst„pienia zró¿nicowanego raka tarczycy. Porównano wartoci pomiarów osoczowego stŒ¿enia Tg odpowiednio
w trakcie stosowania hormonów tarczycy oraz po ich odstawieniu. U wszystkich badanych wykluczono obecnoæ prze-
ciwcia‡ przeciwko Tg. Przyjmuj„c pomiary stŒ¿enia Tg w okresie odstawienia hormonów tarczycy jako z‡oty standard,
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przeanalizowano (ustalaj„c czu‡oæ, specyficznoæ oraz dodatni„ i ujemn„ wartoæ predylekcyjn„) wyniki oznaczeæ stŒ¿e-
nia Tg podczas przyjmowania hormonów tarczycy pod k„tem diagnostyki resztkowej/nawrotowej choroby.
Wyniki: rednie osoczowe stŒ¿enie Tg w warunkach stosowania terapii supresyjnej za pomoc„ podawanych egzogen-
nych hormonów tarczycy wynosi‡o 16,5 ng/ml, natomiast po zaprzestaniu stosowania tyroksyny  95,0 ng/ml (wartoæ
p = 0,001). U 6 chorych (23%) przyjmuj„cych hormony tarczycy stŒ¿enie Tg nie potwierdza‡o wznowy procesu nowotwo-
rowego. Przy za‡o¿eniu, ¿e pomiary stŒ¿enia Tg w okresie odstawienia hormonalnych preparatów tarczycy stanowi„ z‡o-
ty standard, czu‡oæ, specyficznoæ, dodatnia i ujemna wartoæ predylekcyjna wynosi‡y odpowiednio: 72,7%, 100%, 100%
i 40%.
Wnioski: Monitorowanie stŒ¿enia Tg w trakcie terapii tyroksyn„ nie jest wiarygodn„ metod„ w wykrywaniu wznowy
choroby u chorych na zró¿nicowanego raka tarczycy.
(Endokrynol Pol 2007; 58 (2): 100104)
S‡owa kluczowe: rak tarczycy, tyreoglobulina w surowicy, lewotyroksyna, wznowa
Introduction
Differentiated thyroid carcinomas (DTC) are the most
common malignancies of the endocrine system [1] and
with current strategies most patients will achieve a de-
finitive cure and have a normal quality of life. Current
treatments, including total thyroidectomy and ablation
therapy with radio-iodine [1], have had quite remarka-
ble successes in completely eradicating the disease. This
progress in treatment as well as the fairly well-diffe-
rentiated character of these malignancies has led to re-
latively long survival and good prognosis. Although this
is both pleasant and inspiring for patients, it indicates
the need for long-term follow-up [2] in order for ap-
propriate treatment to be applied promptly on the ap-
pearance of any sign of recurrence or residual disease
with the aim of eradicating it.
At present the most widely accepted strategy for the
follow-up management of DTC patients consists of
whole-body 131I scanning (WBS) and serum thyroglo-
bulin (Tg) measurements [3]. Previous researches have
shown that the sensitivity of serum Tg is satisfactory
while the thyroid-stimulating hormone (TSH) level is
high and in this situation it can be used as an appro-
priate test for the follow-up of patients and as a reliable
screening test to assess disease recurrence [1, 410]. The
use of high-quality serum Tg measurements can signi-
ficantly improve the cost-effective management of this
disease by identifying low-risk patients in whom pe-
riodic radio-iodine scans or therapy may be deferred in
favour of serial serum Tg monitoring. Nevertheless,
a rising TSH level requires thyroid hormone withdra-
wal for about 3 to 4 weeks (off-treatment measurement
of Tg) or administration of recombinant human TSH
(rhTSH), each of which will pose some problems.
First, the withdrawal of the hormone, assumed to
be the gold standard, subjects patients to the symptoms
and complications of hypothyroidism, which is not ple-
asant for the patient [5] and theoretically also results in
an increased risk of recurrence [5]. Apart from this,
rhTSH is not available everywhere (as is the case in our
country) and is also somewhat expensive. Finally, the
use of Tg measurement under rhTSH-stimulation has
not been accepted generally as a sensitive and reliable
test. These problems have led to the follow-up of these
patients frequently being done by Tg measurement,
while TSH is inhibited (on-treatment) [2, 4, 5].
The purpose of our study was to assess the efficacy
of on-treatment Tg measurement and to determine its
efficacy in detecting recurrent/persistent disease in those
DTC patients who have a high risk of recurrence and
residual disease.
Material and methods
We performed a large retrospective review of the me-
dical records of patients suffering from DTC who were
assessed, followed and treated for papillary or follicu-
lar thyroid carcinomas (DTC) in our Nuclear Medicine
Ward between 1995 and 2005. Of this population only
those were included in the study who had a history of
total thyroidectomy and radio-iodine ablation therapy
for DTC and who had subsequently, during the course
of follow-up, developed high levels of Tg with negati-
ve WBS. These patients were regarded as a high-risk
sub-group for remnant/recurrent disease and selected
for final analysis. Six months after radio-iodine treat-
ment for elevated Tg and negative WBS the results of
Tg measurement in two TSH suppression and TSH ele-
vation states were recorded and compared with each
other. Only those patients in whom all three tests, na-
mely TSH, Tg and anti-Tg, in both on-treatment and
off-treatment states, had been performed in the wards
own laboratory were entered for analysis.
In all cases treatment with levothyroxine had been
stopped 46 weeks before the Tg measurement and dia-
gnostic whole-body scanning, and these two diagno-
stic tests were performed 2 weeks after discontinuation
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of a 2-week course of liothyronine consumption. The
serum levels of TSH and anti-Tg antibody were measu-
red by IRMA (RADIM/Italy) and the Tg tests was me-
asured by the RIA method (CIS Bio international, Fran-
ce). A serum Tg level of more than 1ng/ml was conside-
red positive [9, 11], while tests for anti-Tg antibodies
were negative in all patients (titer < 1:100).
With the off-treatment measurement of Tg as the gold
standard, the results of the on-treatment measurement of
Tg in diagnosis of remnant/recurrent disease were analysed
for sensitivity, specificity, negative predictive value (NPV)
and positive predictive value (PPV). SPSS for the Windows
software package (Release 11.5.0, SPSS Inc, Chicago, IL) was
used for statistical analysis. Serum Tg levels before and after
withdrawal of thyroid hormone were compared by using
the sign test for all patients. When more than one post-with-
drawal Tg was available, the lowest value was used. A P
value of 0.05 or less was considered significant.
Results
Complete data was obtained for a total of 26 patients,
10 men and 16 women with a mean age of 42.3 yr –
– 17.4 years, and therefore these were accepted for
final analysis. Twenty-three patients had papillary and
three had follicular thyroid cancer. The mean interval
between on-treatment Tg measurement and off-treat-
ment Tg measurement was 36.2 – 4.6 days, above
27 and below 46 days in all patients. At the time of the
off-treatment Tg measurement the mean serum TSH
level was 46.8 mIU/litre (median: 41.9 mIU/litre), and
all patients had a serum TSH level above 35 mIU/litre.
The mean serum TSH level at the time of on-treatment
measurement of Tg was 0.6 mIU/litre (median: 0.4 mIU/
/litre) and in all patients was below 1.4 mIU/litre.
The median serum Tg level under thyroid hormone
suppressive therapy (on-treatment Tg) was 16.5 ng/ml (ran-
ge 0.2210). After withdrawal of thyroid hormone sup-
pressive therapy the median Tg (off-treatment Tg) was
95.0 ng/ml (range 1.5470). The difference was statistically
significant (P value = 0.001). The ratio of the off-treatment
Tg to on-treatment Tg was 11.4 – 14.4 (range 1.95 to 51.2).
Mean values are expressed in Figure 1 (on-treatment mean
Tg level: 39.1, off-treatment mean Tg level: 158.1).
In general, the on-treatment Tg level missed the recur-
rence of the disease in 6 patients (23%). In fact, regarding
the off-treatment Tg as the gold standard, the sensitivity,
specificity, PPV and NPV of the on-treatment Tg measure-
ments were 72.7%, 100%, 100%, and 40% respectively.
Discussion
Measurement of serum thyroglobulin has been reco-
gnised as a sensitive and valuable tool for screening re-
sidual/recurrent disease in patients previously treated
by thyroidectomy and radio-iodine ablation therapy.
In fact, after total thyroidectomy and radio-iodine rem-
nant ablation serum Tg should be undetectable where
there is complete remission. As mentioned earlier, it is
not infrequent for the serum Tg level to be measured
while the patient is on treatment with thyroid hormo-
ne and TSH is suppressed [2, 4, 5, 9, 12]. However, to-
day on-treatment Tg measurement is considered to be
insufficient and Tg measurement under TSH elevation
(after withdrawal of the thyroid hormone over 46 we-
eks or under recombinant TSH intramuscularly) is tho-
ught to be the most reliable indicator for persistent or
recurrent disease. The rationale for the use of TSH sti-
mulation is the well-documented appreciable percen-
tage of patients having false-negative Tg measurements
during levothyroxine treatment when no TSH stimula-
tion is employed: 20% of patients with lymph node
metastases and 5% of patients with distant metastases
but normal plain radiographs [5, 8].
However, as mentioned earlier, the withdrawal of
the hormone subjects patients to the symptoms and
complications of hypothyroidism. A non-randomised
French multicentre study found a mean 13.7 days of
missed work per follow-up with levothyroxine with-
drawal in patients working outside the home (J Leclere,
Satellite Symposium Presentation at the European
Association of Nuclear Medicine Congress, Paris, Fran-
ce, 3 September 2000) [5]. The corresponding data from
a German tertiary referral centre were 11 days missed
with levothyroxine withdrawal (Luster M, Felbinger R,
Figure 1. The difference between mean on-treatment and off-
treatment Tg levels is statistically significant
Rycina 1. Statystycznie istotne ró¿nice miŒdzy rednimi
wartociami osoczowych stŒ¿eæ Tg w okresie otrzymywania
i nieotrzymywania preparatów hormonów tarczycy
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Dietlein M & Reiners C, unpublished observation) [5].
Hence several authors have also used the on-treatment
Tg levels as their screening tool and mentioned that
DTC patients who have an undetectable serum Tg on
thyroid hormone therapy (a TSH-suppressed measu-
rement of Tg) in the absence of Tg-antibody interferen-
ce are considered to be at low risk for residual/recur-
rent disease [2, 4, 5, 9, 12]; the same approach is widely
used in current clinical practice.
There have also been a few trials to reduce the need
for TSH elevation and therefore decrease the incidence
of symptomatology of severe hypothyroidism in the
follow-up of patients with DTC. Guimaraes and DeGro-
ot emphasised that this severe hypothyroidism produ-
ces fatigue, weight gain, depression, inability to carry
out usual activities and occasionally significant illness.
They compared the efficacy of inducing moderate hy-
pothyroidism by cutting replacement therapy by half to
the standard method and reported that a reduction in
the thyroxine replacement dosage to half the usual amo-
unt allowed sufficient elevation of TSH for the measure-
ment of Tg levels after 5 weeks in most patients [13].
Despite these reports our study findings indicate
that on-treatment measurement of Tg is not reliable for
all cases. In fact the measurement of serum Tg under
thyroid hormone replacement therapy is not a sensiti-
ve and reliable screening tool, at least in those patients
who are at high risk of recurrent/residual disease. In
our study this approach (on-treatment measurement of
Tg) missed 6 patients who actually needed further tre-
atment and on the basis of its results 23% of patients mis-
sed the opportunity of receiving further therapeutic inte-
rventions. Indeed a sensitivity of ~73% is not acceptable
for an ideal screening test. Our study findings are also in
agreement with Eustatia-Rutten et al. [6], who previously
stated that the best accuracy of Tg-guided follow-up in
patients treated for differentiated thyroid carcinoma is
obtained if Tg testing is performed while off levothyro-
xine treatment. This fact was also previously mentio-
ned in nuclear medicine literature: the sensitivity of Tg
is much higher under TSH elevation > 30 mU/I (98%)
than under TSH-suppressive thyroid hormone thera-
py (80%) [14]. In a large multicentre trial that included
30 patients with 131I uptake outside the thyroid bed an
elevated Tg level (> 2 ng/ml) was detected in only 80% of
those taking thyroid hormone but was found in 100% of
patients given rhTSH or who had experienced withdra-
wal of thyroid hormone [15]. It is generally reported that
only 90% of patients with metastasis have an elevated Tg
level during thyroid hormone therapy [16]. Mazzaferri et al.
have also emphasised that an undetectable serum Tg me-
asured during thyroid hormone suppression of TSH is
often misleading [10]. These authors noted that 21% of
patients who had no clinical evidence of tumours with
baseline on-treatment serum Tg levels (usually below 1 mi-
cro g/litre) showed, in response to recombinant human TSH
(rhTSH), a rise in serum Tg to more than 2 micro g/litre.
Our study also shows that the mean level of serum
Tg will increase more than eleven-fold following thy-
roid hormone withdrawal. The same finding was pre-
viously reported by Schlumberger et al. [5] and these
authors noted that TSH stimulation will increase serum
Tg values by about ten-fold over baseline levels. As expla-
ined earlier by Spencer et al. [9], serum Tg levels princi-
pally integrate three variables: the mass of thyroid tissue
present (benign or neoplastic), the degree of thyrotropin
(TSH) receptor stimulation and a tumours intrinsic abi-
lity to synthesise and secrete Tg. It should be emphasi-
sed that serum Tg measurements should be interpreted
relative to the TSH status of the patient. When TSH is
low, basal serum Tg may be undetectable and TSH ele-
vation (via rhTSH injection or thyroid hormone with-
drawal) may be needed to increase serum Tg into the
measurable range. The proportionate Tg response to
rhTSH (rhTSH-stimulated Tg/basal Tg) is an index of the
tumours sensitivity to TSH. Normal thyroid remnant and
well-differentiated thyroid tumours display a greater
(> 10-fold) serum Tg response to TSH stimulation than
less well-differentiated tumours (< 3-fold) [9].
Zakavi et al. [17] also reported that serum Tg incre-
ment after thyroid hormone discontinuation seems to
be a better predictor of tumour recurrence, although
a minimal Tg increment may not be a specific marker.
Fifty-five patients with DTC treated with thyroidecto-
my and 131I were enrolled. Serum Tg levels increased
> or = 1 ng/ml in 25 patients after discontinuation of
levothyroxine. Of these, 17 patients had metastatic dise-
ase or a detectable thyroid remnant. Of 16 patients with
unchanged serum Tg levels (1 < Delta Tg < +1), three
had a thyroid remnant or metastases. In 14 patients with
Tg decrement (Delta < or = 1) only two had a thyroid
remnant. The positive predictive value for a Tg incre-
ment of more than 1, 2 and 5 ng/ml was 68%, 77.2% and
88.9% respectively. The authors concluded that DeltaTg
is a more reliable indicator of remnant disease than on-
treatment Tg or even off-treatment Tg levels [17].
Conclusion
Normal serum thyroglobulin level without on-treat-
ment of thyroid-stimulating hormone is not diagnosti-
cally reliable in the follow-up of differentiated thyroid
cancer patients with a high probability of residual/re-
current or metastatic disease.
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